{"id":"NCT01217606","sponsor":"Allergan","briefTitle":"Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-01","primaryCompletion":"2014-09","completion":"2015-06","firstPosted":"2010-10-08","resultsPosted":"2015-11-09","lastUpdate":"2016-12-20"},"enrollment":185,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Glaucoma, Open-Angle","Ocular Hypertension"],"interventions":[{"type":"DRUG","name":"bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)","otherNames":[]},{"type":"DRUG","name":"Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution","otherNames":["COMBIGAN®"]}],"arms":[{"label":"Triple Combination Therapy","type":"EXPERIMENTAL"},{"label":"Combigan®","type":"ACTIVE_COMPARATOR"}],"summary":"This study will evaluate the safety and efficacy of Triple Combination Therapy compared with Fixed Combination brimonidine tartrate/timolol ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension.","primaryOutcome":{"measure":"Change From Baseline in Mean Worse Eye Intraocular Pressure (IOP) Analyzed by Two-Sample T-Test","timeFrame":"Baseline, Week 12","effectByArm":[{"arm":"Triple Combination Therapy","deltaMin":25.42,"sd":2.902},{"arm":"Combigan®","deltaMin":24.43,"sd":2.592}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":5},"locations":{"siteCount":1,"countries":["Brazil"]},"refs":{"pmids":["32089329"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":90},"commonTop":["Conjunctival hyperaemia","Punctate keratitis","Blepharitis","Conjunctival follicles","Eye pruritus"]}}